Eloisa Yuste

List of Publications by Year in descending order

34 papers	1,497 citations	393982 19 h-index	377514 34 g-index
34 all docs	34 docs citations	34 times ranked	2296 citing authors

#	Article	IF	Citations
1	Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Medicine, 2009, 15, 901-906.	15.2	279
2	Drastic Fitness Loss in Human Immunodeficiency Virus Type 1 upon Serial Bottleneck Events. Journal of Virology, 1999, 73, 2745-2751.	1.5	160
3	Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5Â. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19134-19139.	3.3	149
4	A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology, 2007, 360, 329-340.	1.1	94
5	Modulation of Env Content in Virions of Simian Immunodeficiency Virus: Correlation with Cell Surface Expression and Virion Infectivity. Journal of Virology, 2004, 78, 6775-6785.	1.5	80
6	Simian Immunodeficiency Virus Engrafted with Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Epitopes: Replication, Neutralization, and Survey of HIV-1-Positive Plasma. Journal of Virology, 2006, 80, 3030-3041.	1.5	72
7	Gold Nanoparticles Coated with Oligomannosides of HIV-1 Glycoprotein gp120 Mimic the Carbohydrate Epitope of Antibody 2G12. Journal of Molecular Biology, 2011, 410, 798-810.	2.0	72
8	Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein Journal of Organic Chemistry, 2014, 10, 1339-1346.	1.3	69
9	Unusual Distribution of Mutations Associated with Serial Bottleneck Passages of Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 9546-9552.	1.5	49
10	Virion Envelope Content, Infectivity, and Neutralization Sensitivity of Simian Immunodeficiency Virus. Journal of Virology, 2005, 79, 12455-12463.	1.5	49
11	In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. Journal of General Virology, 2002, 83, 93-101.	1.3	44
12	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	1.7	38
13	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology, 2011, 85, 5804-5813.	1.5	37
14	Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIVmac239. PLoS Pathogens, 2009, 5, e1000272.	2.1	32
15	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. Journal of Virology, 2016, 90, 5231-5245.	1.5	31
16	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	1.1	24
17	Potent Antibody-Mediated Neutralization and Evolution of Antigenic Escape Variants of Simian Immunodeficiency Virus Strain SIVmac239 In Vivo. Journal of Virology, 2008, 82, 9739-9752.	1.5	23
18	Glycosylation of gp41 of Simian Immunodeficiency Virus Shields Epitopes That Can Be Targets for Neutralizing Antibodies. Journal of Virology, 2008, 82, 12472-12486.	1.5	22

#	Article	IF	Citations
19	Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. PLoS ONE, 2012, 7, e31928.	1.1	21
20	Evidence against Extracellular Exposure of a Highly Immunogenic Region in the C-Terminal Domain of the Simian Immunodeficiency Virus gp41 Transmembrane Protein. Journal of Virology, 2012, 86, 1145-1157.	1.5	19
21	Few Mutations in the 5â€² Leader Region Mediate Fitness Recovery of Debilitated Human Immunodeficiency Type 1 Viruses. Journal of Virology, 2005, 79, 5421-5427.	1.5	18
22	Evolution of Broadly Cross-Reactive HIV-1-Neutralizing Activity: Therapy-Associated Decline, Positive Association with Detectable Viremia, and Partial Restoration of B-Cell Subpopulations. Journal of Virology, 2013, 87, 12227-12236.	1.5	18
23	Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1139-1148.	1.1	18
24	Frequency-dependent selection in human immunodeficiency virus type 1. Journal of General Virology, 2002, 83, 103-106.	1.3	17
25	Structural Study of a New HIVâ€1 Entry Inhibitor and Interaction with the HIVâ€1 Fusion Peptide in Dodecylphosphocholine Micelles. Chemistry - A European Journal, 2017, 23, 11703-11713.	1.7	10
26	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	1.5	10
27	Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 601-609.	1.7	9
28	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE, 2018, 13, e0208345.	1.1	8
29	HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds. Current Medicinal Chemistry, 2013, 21, 238-250.	1.2	8
30	Systematic Analysis of Intracellular Trafficking Motifs Located within the Cytoplasmic Domain of Simian Immunodeficiency Virus Glycoprotein gp41. PLoS ONE, 2014, 9, e114753.	1.1	6
31	HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity. PLoS ONE, 2015, 10, e0134054.	1.1	5
32	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. Journal of Translational Medicine, 2013, 11, 48.	1.8	3
33	Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope. Vaccines, 2022, 10, 484.	2.1	2
34	Antibody-Based Preventive and Therapeutic Strategies Against HIV. Current HIV Research, 2016, 14, 260-269.	0.2	1